Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bendamustine in rituximab-refractory indolent NHL
CTR20132892Phase 3Completed
- Sponsor
- Pinxin Pharma
- Start
- Apr 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of bendamustine in myeloid/lymphoid neoplasm with eosinophilia and FLT3 rearrangement, sponsored by Pinxin Pharma. Started Apr 2014; status: completed.
02
Drugs
bendamustine
03
Conditions
myeloid/lymphoid neoplasm with eosinophilia and FLT3 rearrangement
Beyond the preview
Go deeper on CTR20132892.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20132892.